NCT04607733View on ClinicalTrials.gov

A Study of Mirikizumab in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

November 2, 2020

Primary Completion Date

May 17, 2021

Study Completion Date

May 17, 2021

Conditions
Healthy
Interventions
DRUG

Mirikizumab Prefilled Syringe

Administered SC by prefilled syringe

DRUG

Mirikizumab Autoinjector

Administered SC by autoinjector

Trial Locations (4)

32117

Covance Clinical Research Inc, Daytona Beach

53704

Covance Clinical Research Inc, Madison

65802

QPS, Springfield

75247

Covance Dallas, Dallas

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04607733 - A Study of Mirikizumab in Healthy Participants | Biotech Hunter | Biotech Hunter